Radiopharm Theranostics Limited (RADX) Income Statement
RADX FY2026 at a glance
Fiscal year ended June 30, 2026 · U.S. dollarsRADX revenue and net income
Where RADX's revenue goes
FY2026Each bar shows an amount and its share of revenue. RADX kept −1,992.5% of revenue as net income.
RADX profit margins
RADX growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
RADX quarterly EPS vs estimates
Radiopharm Theranostics Limited beat the analyst EPS estimate in 1 of the last 1 quarters.
RADX income statement
| FY2026 | |
|---|---|
| Revenue | $2.7M |
| Cost of revenue | $4.8M |
| Gross profit | −$2.1M |
| Total operating expenses | $64.7M |
| Operating income | −$66.8M |
| Interest expense | $109,939 |
| Income before taxes | −$55.7M |
| Income taxes | −$53,249 |
| Net income | −$53.9M |
| EBITDA | −$64.1M |
| EPS (diluted) | −$1369.14 |
| Gross margin | −77.7% |
| Operating margin | −2,468.6% |
| Net margin | −1,992.5% |
| Jun '26 | Dec '25 | |
|---|---|---|
| Revenue | $1.4M | $1.4M |
| Cost of revenue | $1.2M | $2.6M |
| Gross profit | $162,568 | −$1.2M |
| Research & development | — | $19.6M |
| Total operating expenses | $40.1M | $29.3M |
| Operating income | −$39.9M | −$30.5M |
| Interest expense | $47,957 | $63,908 |
| Income before taxes | −$29.2M | −$32.1M |
| Income taxes | −$191,405 | −$4.3M |
| Net income | −$28.6M | −$26.5M |
| EBITDA | −$39.9M | −$29.2M |
| EPS (diluted) | — | $0.00 |
| Gross margin | 11.6% | −90.3% |
| Operating margin | −2,847.2% | −2,245.0% |
| Net margin | −2,038.8% | −1,946.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in RADX's financial statements (latest annual report filed September 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
RADX financial results
In fiscal year 2026 (ended June 30, 2026), Radiopharm Theranostics Limited reported revenue of $2.7 million. It had a net loss of $53.9 million, a net profit margin of −1,992.5%. Diluted earnings per share came to −$1369.14.
See the RADX stock overview for the latest quote and news, or the RADX chart for price history and technical indicators.
RADX income statement FAQ
What is Radiopharm Theranostics Limited's annual revenue?
Radiopharm Theranostics Limited reported total revenue of $2.7 million for fiscal year 2026, which ended on June 30, 2026.
Is Radiopharm Theranostics Limited profitable?
No. Radiopharm Theranostics Limited reported a net loss of $53.9 million in fiscal 2026, a net profit margin of −1,992.5%; its operating margin was −2,468.6%.
What is Radiopharm Theranostics Limited's gross margin?
Radiopharm Theranostics Limited's gross margin was −77.7% in fiscal 2026: for every $100 of revenue, Radiopharm Theranostics Limited kept $-78 after the direct cost of its products and services.
What are Radiopharm Theranostics Limited's earnings per share?
Radiopharm Theranostics Limited earned $-1369.14 per diluted share in fiscal 2026.
When does Radiopharm Theranostics Limited's fiscal year end?
Radiopharm Theranostics Limited's fiscal year ends in June. The latest annual report covers the year ended June 30, 2026 and was filed on September 30, 2026.